Clinical Characteristics of 80 Patients With MCL
| Characteristic . | No. of Patients (%) . |
|---|---|
| Age at presentation | |
| ≤60 yr | 29 (36) |
| >60 yr | 51 (64) |
| Sex | |
| Male | 56 (70) |
| Female | 24 (30) |
| Primary site of involvement at presentation | |
| Lymph node | 60 (75) |
| Extranodal | 20 (25) |
| Waldeyer's ring | 5 (6) |
| Intestine | 4 (5) |
| Orbit | 2 (3) |
| Salivary gland | 2 (3) |
| Stomach | 2 (3) |
| Breast | 1 (1) |
| Epidural | 1 (1) |
| Liver | 1 (1) |
| Pleura | 1 (1) |
| Spleen | 1 (1) |
| Ann Arbor stage | |
| I | 5 (6) |
| II | 6 (6) |
| III | 11 (14) |
| IV | 57 (71) |
| Not staged* | 1 (1) |
| B symptoms | |
| Present | 19 (24) |
| Absent | 61 (76) |
| Serum LDH level | |
| Normal | 34 (43) |
| Elevated | 22 (27) |
| Unknown | 24 (30) |
| PS (ECOG) | |
| 0, 1 | 45 (56) |
| 2-4 | 12 (15) |
| Unknown | 23 (29) |
| No. of extranodal sites at presentation | |
| None | 18 (23) |
| 1 | 25 (31) |
| >1 | 37 (46) |
| Characteristic . | No. of Patients (%) . |
|---|---|
| Age at presentation | |
| ≤60 yr | 29 (36) |
| >60 yr | 51 (64) |
| Sex | |
| Male | 56 (70) |
| Female | 24 (30) |
| Primary site of involvement at presentation | |
| Lymph node | 60 (75) |
| Extranodal | 20 (25) |
| Waldeyer's ring | 5 (6) |
| Intestine | 4 (5) |
| Orbit | 2 (3) |
| Salivary gland | 2 (3) |
| Stomach | 2 (3) |
| Breast | 1 (1) |
| Epidural | 1 (1) |
| Liver | 1 (1) |
| Pleura | 1 (1) |
| Spleen | 1 (1) |
| Ann Arbor stage | |
| I | 5 (6) |
| II | 6 (6) |
| III | 11 (14) |
| IV | 57 (71) |
| Not staged* | 1 (1) |
| B symptoms | |
| Present | 19 (24) |
| Absent | 61 (76) |
| Serum LDH level | |
| Normal | 34 (43) |
| Elevated | 22 (27) |
| Unknown | 24 (30) |
| PS (ECOG) | |
| 0, 1 | 45 (56) |
| 2-4 | 12 (15) |
| Unknown | 23 (29) |
| No. of extranodal sites at presentation | |
| None | 18 (23) |
| 1 | 25 (31) |
| >1 | 37 (46) |
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group.
Patient not staged because of severe coincident multiple sclerosis.